Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 2Completed 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Tumor-Agnostic 1Gastrointestinal 1CNS 1

Conditions

Stomach Neoplasms 1Neoplasms 1Brain Neoplasms 1

Interventions

pembrolizumab 1285Specimen Handling 928Carboplatin 837Magnetic Resonance Spectroscopy 834Cyclophosphamide 808Cisplatin 736Nivolumab 681Paclitaxel 635Radiotherapy 618Gemcitabine 580Biopsy 560Bevacizumab 486Dexamethasone 444fludarabine 410Docetaxel 385venetoclax 372Oxaliplatin 367Capecitabine 363Fluorouracil 358atezolizumab 353durvalumab 340Rituximab 336Drug Therapy 334Radiosurgery 321Doxorubicin 320Blood Specimen Collection 317Standard of Care 311Pemetrexed 308Ipilimumab 303Radiation 289

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Angiogenesis Inhibitors × 1 year × Clear all
NCT07389876 2026-02-05

G/GEJ

Fudan University

Recruiting
250 enrolled
Gastrointestinal

Stomach Neoplasms

NCT06840119 2026-01-28

Phase 1/2 Study of IMC-R117C in Selected Advanced Cancers

Immunocore Ltd

Phase 1/2 Recruiting
600 enrolled
Tumor-Agnostic

Neoplasms

NCT03890952 2025-07-24

Translational Study of Nivolumab in Combination With Bevacizumab for Recurrent Glioblastoma

Rigshospitalet, Denmark

Phase 2 Completed
40 enrolled
CNS

Brain Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡